{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:25:28Z","timestamp":1787030728307,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03216-x","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:24:55Z","timestamp":1781252695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Camilla Fuchs","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Hempel","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massar","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Nouhravesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Kistorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Tuxen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Lyng","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip Soeskov","family":"Davidovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rugivan","family":"Sabaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"H\u00f8jlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Eifer","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"3216_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"3216_CR2","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, A SD, Butler J. Cardiovascular and renal outcomes with Empagliflozin in heart failure. Empagliflozin Outcome Trial in patients with chronic heart failure and a reduced ejection fraction - EMPEROR-Reduced. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"3216_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"W Herrington","year":"2023","unstructured":"Herrington W, Staplin N, Wanner C, Green J, Hauske S, Emberson J, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","journal-title":"N Engl J Med"},{"key":"3216_CR4","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148:1606\u201335.","journal-title":"Circulation"},{"key":"3216_CR5","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.atherosclerosis.2005.03.010","volume":"183","author":"DB Panagiotakos","year":"2005","unstructured":"Panagiotakos DB, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis. 2005;183:308\u201315.","journal-title":"Atherosclerosis"},{"key":"3216_CR6","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1161\/01.CIR.0000057810.48709.F6","volume":"107","author":"RS Vasan","year":"2003","unstructured":"Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486\u201391.","journal-title":"Circulation"},{"key":"3216_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01268-1","volume":"16","author":"T Mao","year":"2024","unstructured":"Mao T, He Q, Yang J, Jia L, Xu G. Relationship between gout, hyperuricemia, and obesity: does central obesity play a significant role?\u2014a study based on the NHANES database. Diabetol Metab Syndr. 2024;16:24.","journal-title":"Diabetol Metab Syndr"},{"key":"3216_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","volume":"16","author":"H Huang","year":"2014","unstructured":"Huang H, Huang B, Li Y, Huang Y, Li J, Yao H, et al. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014;16:15\u201324.","journal-title":"Eur J Heart Fail"},{"key":"3216_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cells11132005","author":"R Sabaratnam","year":"2022","unstructured":"Sabaratnam R, Skov V, Paulsen SK, Juhl S, Kruse R, Hansen T, et al. A signature of exaggerated adipose tissue dysfunction in type 2 diabetes is linked to low plasma adiponectin and increased transcriptional activation of proteasomal degradation in muscle. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11132005.","journal-title":"Cells"},{"issue":"1","key":"3216_CR10","doi-asserted-by":"publisher","first-page":"e006277","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","volume":"13","author":"NJ Byrne","year":"2020","unstructured":"Byrne NJ, Matsumura N, Maayah ZH, Ferdaoussi M, Takahara S, Darwesh AM, et al. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ Heart Fail. 2020;13(1):e006277.","journal-title":"Circ Heart Fail"},{"key":"3216_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, Lee S-G, Kim SH, Kim JH, Choi E, Cho W, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11:2127.","journal-title":"Nat Commun"},{"key":"3216_CR12","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1111\/dom.15586","volume":"26","author":"L Buttice","year":"2024","unstructured":"Buttice L, Ghani M, Suthakar J, Gnanalingham S, Carande E, Kennedy BWC, et al. The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26:2706\u201321.","journal-title":"Diabetes Obes Metab"},{"key":"3216_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12902-023-01512-1","volume":"23","author":"S Gohari","year":"2023","unstructured":"Gohari S, Ismail-Beigi F, Mahjani M, Ghobadi S, Jafari A, Ahangar H, et al. The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials. BMC Endocr Disord. 2023;23:257.","journal-title":"BMC Endocr Disord"},{"key":"3216_CR14","doi-asserted-by":"publisher","first-page":"1045235","DOI":"10.3389\/fphar.2022.1045235","volume":"13","author":"D Wang","year":"2022","unstructured":"Wang D, Liu J, Zhong L, Li S, Zhou L, Zhang Q, et al. The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13:1045235.","journal-title":"Front Pharmacol"},{"key":"3216_CR15","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1111\/dom.15483","volume":"26","author":"A Diallo","year":"2024","unstructured":"Diallo A, Diallo MF, Carlos-Bolumbu M, Galtier F. Uric acid-lowering effects of sodium-glucose cotransporter 2 inhibitors for preventing cardiovascular events and mortality: a systematic review and meta-analysis. Diabetes Obes Metab. 2024;26:1980\u20135.","journal-title":"Diabetes Obes Metab"},{"key":"3216_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ahj.2024.02.005","volume":"271","author":"CF Andersen","year":"2024","unstructured":"Andersen CF, Larsen JH, Jensen J, Omar M, Nouhravesh N, Kistorp C, et al. Empagliflozin to elderly and obese patients with increased risk of developing heart failure: study protocol for the Empire Prevent trial program. Am Heart J. 2024;271:84\u201396.","journal-title":"Am Heart J"},{"key":"3216_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwag010","author":"CF Andersen","year":"2026","unstructured":"Andersen CF, Larsen JH, Omar M, Nouhravesh N, Kistorp C, Tuxen C, et al. The effect of empagliflozin on fluid volume status and cardiac adipose tissue in patients at risk of heart failure: main results from the empire prevent metabolic trial. Eur J Prev Cardiol. 2026. https:\/\/doi.org\/10.1093\/eurjpc\/zwag010.","journal-title":"Eur J Prev Cardiol"},{"key":"3216_CR18","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/oby.2010.257","volume":"19","author":"MJ Neville","year":"2011","unstructured":"Neville MJ, Collins JM, Gloyn AL, Mccarthy MI. Comprehensive human adipose tissue mRNA and MicroRNA endogenous control selection for quantitative real-time-PCR normalization. Obesity Silver Spring. 2011;19:888\u201392.","journal-title":"Obesity Silver Spring"},{"key":"3216_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","volume":"23","author":"KGMM Alberti","year":"2006","unstructured":"Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469\u201380.","journal-title":"Diabet Med"},{"key":"3216_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","volume":"107","author":"TA Pearson","year":"2003","unstructured":"Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the american heart association. Circulation. 2003;107:499\u2013511.","journal-title":"Circulation"},{"issue":"2","key":"3216_CR21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ejhf.2735","volume":"25","author":"CF Andersen","year":"2022","unstructured":"Andersen CF, Omar M, Glenth\u00f8j A, El FD, M\u00f8ller HJ, Lindholm Kurtzhals JA, et al. Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial. Eur J Heart Fail. 2022;25(2):226\u201334.","journal-title":"Eur J Heart Fail"},{"key":"3216_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac544.2683","volume":"43","author":"P Theofilis","year":"2022","unstructured":"Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis K, et al. Anti-inflammatory potential of SGLT2 inhibitors: a systematic review and meta-analysis of preclinical studies in rodents. Eur Heart J. 2022;43:ehac544.2683.","journal-title":"Eur Heart J"},{"issue":"7","key":"3216_CR23","doi-asserted-by":"publisher","first-page":"102393","DOI":"10.1016\/j.jchf.2024.12.012","volume":"13","author":"KF Docherty","year":"2025","unstructured":"Docherty KF, McDowell K, Welsh P, Petrie MC, Anand I, Berg DD, et al. Interleukin-6 in heart\u00a0failure with reduced ejection fraction and the effect of dapagliflozin: an exploratory analysis of the dapagliflozin and prevention of adverse outcomes in heart\u00a0failure trial. JACC Hear Fail. 2025;13(7):102393.","journal-title":"JACC Hear Fail"},{"key":"3216_CR24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12933-023-01904-6","volume":"22","author":"M Benedikt","year":"2023","unstructured":"Benedikt M, Mangge H, Aziz F, Curcic P, Pailer S, Herrmann M, et al. Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction: a post-hoc analysis of the EMMY trial. Cardiovasc Diabetol. 2023;22:166.","journal-title":"Cardiovasc Diabetol"},{"key":"3216_CR25","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1002\/jmv.26654","volume":"93","author":"EA Said","year":"2021","unstructured":"Said EA, Al-Reesi I, Al-Shizawi N, Jaju S, Al-Balushi MS, Koh CY, et al. Defining IL-6 levels in healthy individuals: a meta-analysis. J Med Virol. 2021;93:3915\u201324.","journal-title":"J Med Virol"},{"key":"3216_CR26","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1161\/01.CIR.0000099542.57313.C5","volume":"108","author":"T Mazurek","year":"2003","unstructured":"Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108:2460\u20136.","journal-title":"Circulation"},{"key":"3216_CR27","doi-asserted-by":"publisher","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","volume":"316","author":"A Novikov","year":"2019","unstructured":"Novikov A, Fu Y, Huang W, Freeman B, Patel R, van Ginkel C, et al. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. Am J Physiol Ren Physiol. 2019;316:F173\u201385.","journal-title":"Am J Physiol Ren Physiol"},{"key":"3216_CR28","doi-asserted-by":"publisher","first-page":"356","DOI":"10.2337\/dc17-1096","volume":"41","author":"SE Inzucchi","year":"2018","unstructured":"Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41:356\u201363.","journal-title":"Diabetes Care"},{"key":"3216_CR29","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cardfail.2020.08.015","volume":"26","author":"M Packer","year":"2020","unstructured":"Packer M. Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors. J Card Fail. 2020;26:977\u201384.","journal-title":"J Card Fail"},{"key":"3216_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40842-023-00156-3","volume":"9","author":"J Lee","year":"2023","unstructured":"Lee J, Kim M, Jang J-Y, Oh C-M. Assessment HOMA as a predictor for new onset diabetes mellitus and diabetic complications in non-diabetic adults: a KoGES prospective chort study. Clin Diabetes Endocrinol. 2023;9:7.","journal-title":"Clin Diabetes Endocrinol"},{"key":"3216_CR31","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, Ljunggren \u00d6, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"3216_CR32","doi-asserted-by":"crossref","unstructured":"Veelen A, Andriessen C, Op den Kamp Y, Erazo-Tapia E, Ligt M de, Mevenkamp J, et al. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: a randomized, double-blind crossover trial. Metabolism. 2023; 140:155396.","DOI":"10.1016\/j.metabol.2022.155396"},{"key":"3216_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-024-06306-1","volume":"68","author":"DT Meier","year":"2025","unstructured":"Meier DT, de Paula Souza J, Donath MY. Targeting the NLRP3 inflammasome-IL-1\u03b2 pathway in type 2 diabetes and obesity. Diabetologia. 2025;68:3\u201316.","journal-title":"Diabetologia"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03216-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03216-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03216-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:27:12Z","timestamp":1787027232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03216-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3216"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03216-x","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Oral and written informed consent were obtained from all participants. The trial was approved by The Regional Committee on Health Research Ethics (no. S-20210028) in the Southern Denmark Region and the Danish Medicines Agency (no. 2021040401). Trial conduct was in alignment with the Danish Health Act, the Declaration of Helsinki, and the standards for Good Clinical Practice.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors take full responsibility for the data in this manuscript and have consented to publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.F.A. reports grants from Danish Heart Foundation, Toyota-Fonden, Arvid Nilsson\u2019s Foundation, Aase & Ejnar Danielsen\u2019s Foundation, Fru Asta Florida Bolding\u2019s Memorial Grant, KV Foundation and The Research and Innovation Foundation of the Department of Cardiology (FUHAS, formerly FUKAP), Herlev and Gentofte University Hospital, Herlev, Denmark, during the conduct of the submitted work; personal fees from AstraZeneca and has acted as an unpaid sub-investigator in two trials from Novo Nordisk, outside the submitted work. J.H.L. reports grants from Danish Heart Foundation, Odense University Hospital Ph.D. Foundation, Steno Diabetes Center Odense Ph.D. Foundation, Eva and Henry Fr\u00e6nkel\u2019s Memorial Grant, Kurt and Grethe B\u00f8nnelykke\u2019s Foundation, Guldsmed A.L. Rasmussen\u2019s Memorial Grant. M.A.O reports grants from the Danish Heart Foundation; The Steno Diabetes Center Odense, Denmark; and the A.P. M\u00f8ller Foundation, outside the submitted work. N.N. reports speaker fees from AstraZeneca and Bayer, all outside the submitted work. C.K. has received speaker fees or served on advisory boards for AstraZeneca, Boehringer Ingelheim, Novartis Genzyme, Amicus and Chiesi. C.T. reports speaker fees from Orion Pharma, personal fees for advisory board participation from Boehringer Ingelheim and Bayer A\/S, all outside the submitted work. F.K.K. has previously served on scientific advisory panels and\/or been part of speaker\u2019s bureaus for, served as a consultant to and\/or received research support from 89bio, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, Lupin, MedImmune, MSD\/Merck, Mundipharma, Norgine, Novo Nordisk, Pharmacosmos, Sanofi, Structure Therapeutics, Zealand Pharma and Zucara; is a co-founder and minority shareholder in Antag Therapeutics; and currently employed by Novo Nordisk. F.S.D reports grants from The CARDIOHGH at the Department of Cardiology, Herlev and Gentofte University Hospital, the Novo Nordisk Foundation and speaker fees from Bayer, all outside the submitted work. L.K. reports speaker fees from AstraZeneca, Boehringer Ingelheim, Novartis and Bayer. K.H. reports grants from the Novo Nordisk Foundation, the Independent Research Fund Denmark, the Region of Southern Denmark, Odense University Hospital, Lilly and Herbert Hansen\u2019s Foundation, Jascha Fonden, the Ministry of Higher Education and Science, and the Danish Diabetes Academy all outside submitted work. M.S. reports grants from The Danish Heart Foundation, during the conduct of the study; personal fees and non-financial support from AstraZeneca, personal fees from Novo Nordisk and Boehringer Ingelheim, outside the submitted work. J.E.M. reports speaker fees from Novartis, Boehringer Ingelheim, Abiomed, Orion and Abbott, advisory board from Orion and Boehringer Ingelheim, and research grant Abiomed and Roche, all outside submitted work. J.J. reports grants from The Capital Region of Denmark; Novo Nordisk (speaker fee), Roche Diagnostics (conference participation) Boehringer Ingelheim (contribution to the KARDINAL study), Bayer (member of the steering committee of the ALPINE 1 trial), all outside the submitted work.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"238"}}